Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a biotechnology company with a mission to discover, develop and deliver curative therapies that address the underlying causes of heart disease, today announced participation in two upcoming investor conferences.
Details of each presentation are as follows:
H.C. Wainwright Gene Therapy and Gene Editing Conference
Fireside chat
Date: March 30, 2022
Time: 7:00 a.m. ET – available on demand
Chardan 6th Annual Genetic Medicines Manufacturing Summit
Fireside chat
Date: April 26, 2022
Time: 1:00 p.m. ET
Webcasts of the fireside chats will be available by visiting the Investors section of Tenaya’s website. A replay of each webcast will be available on the Tenaya website for approximately 30 days following each conference.
About Tenaya Therapeutics
Tenaya Therapeutics is a biotechnology company committed to a bold mission: to discover, develop and deliver curative therapies that address the underlying drivers of heart disease. Founded by leading cardiovascular scientists from Gladstone Institutes and the University of Texas Southwestern Medical Center, Tenaya is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. For more information, visit www.tenayatherapeutics.com.
| Last Trade: | US$1.83 |
| Daily Change: | 0.06 3.39 |
| Daily Volume: | 4,061,955 |
| Market Cap: | US$298.250M |
August 06, 2025 May 07, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
